Clinical Trial Update: Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing duration of androgen receptor pathway inhibitor therapy with androgen deprivation therapy plus metastasis-directed therapy in o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Androgen deprivation therapy (Androgen deprivation therapy)
• Androgen receptor pathway inhibitor (androgen receptor pathway inhibitor)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Metastatic Prostate Cancer | Phase 2 | Status: RECRUITING